Therapeutic outcomes of TP53-mutated diffuse large B cell lymphoma: A systematic review and meta-analysis.
Meta-analysis establishes remission rates for a high-risk lymphoma subtype, revealing substantial differences across studies and reinforcing the need for dedicated clinical trials.
Meta-analysis of 31 studies (n=1164) establishes pooled remission benchmarks for TP53-mutated DLBCL: 60% CR with targeted therapy plus chemotherapy in newly diagnosed, and 39% CR with CAR-T in relapsed/refractory disease. High between-study heterogeneity reflects heterogeneous TP53m DLBCL biology and reinforces need for dedicated prospective trials in this high-risk lymphoma group.
What the study was
- Study design
- Systematic review and meta-analysis; 31 studies, 1164 TP53-mutated DLBCL patients.
- Population
- 1164 patients with TP53-mutated DLBCL across 31 studies.
- Sample size
- 1164
- Category
- Treatment Innovation
- Maturity
- Validated
- Journal
- iScience
Why it surfaced
Meta-analysis establishes evidence benchmarks for TP53m DLBCL; important reference for trial design in this high-risk lymphoma group.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.